Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H40O2 |
| Molecular Weight | 360.5732 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4CCCC[C@]4(C)[C@H]3CC[C@]12C
InChI
InChIKey=RPKLZQLYODPWTM-LVVAJZGHSA-N
InChI=1S/C24H40O2/c1-16(7-12-22(25)26)19-10-11-20-18-9-8-17-6-4-5-14-23(17,2)21(18)13-15-24(19,20)3/h16-21H,4-15H2,1-3H3,(H,25,26)/t16-,17+,18+,19-,20+,21+,23+,24-/m1/s1
| Molecular Formula | C24H40O2 |
| Molecular Weight | 360.5732 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cholanic acid is the archetypal C24 bile acid skeleton from which all other C24 bile acids can be derived. Of the two common isomers: 5alpha and 5Beta, the last isomer is the most biologically relevant. 5-Beta Cholanic Acid has been studied as a modulator of the gamma-secretase complex as it pertains to Alzheimer's disease; it has also been identified as an inhibitor of the Ephrin type-A receptor 2 that is involved in cancer cell signaling and angiogenesis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P29317 Gene ID: 1969.0 Gene Symbol: EPHA2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24152675 |
4.91 null [pIC50] | ||
Target ID: CHEMBL2094135 |
5.7 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator. | 2015-07-14 |
|
| Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. | 2013-10-21 |
|
| Steroids as γ-secretase modulators. | 2013-09 |
|
| Structure and origin of bile acids: an overview. | 2006-12-02 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14490705
Curator's Comment: The referenced study was conducted in rat.
C14 labeled cholanic acid sodium salt was administered intraperitoneally at a dose of 0.7 mg (1.54 x 10^6 d.p.m. per mg) to rats with bile fistulas, and rats with ligated bile ducts. The excreta was monitored for C14 labeled metabolites.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24152675
PC3 human prostate adenocarcinoma cells were grown in Ham F12 media. 5B-cholanic acid was stocked as 5 mM solution in DMSO and tested in a 96 well ELISA displacement assay starting at 50 microM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:21:02 GMT 2025
by
admin
on
Mon Mar 31 22:21:02 GMT 2025
|
| Record UNII |
970EKW2JTO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
92803
Created by
admin on Mon Mar 31 22:21:02 GMT 2025 , Edited by admin on Mon Mar 31 22:21:02 GMT 2025
|
PRIMARY | |||
|
18161
Created by
admin on Mon Mar 31 22:21:02 GMT 2025 , Edited by admin on Mon Mar 31 22:21:02 GMT 2025
|
PRIMARY | |||
|
DTXSID501021288
Created by
admin on Mon Mar 31 22:21:02 GMT 2025 , Edited by admin on Mon Mar 31 22:21:02 GMT 2025
|
PRIMARY | |||
|
36238
Created by
admin on Mon Mar 31 22:21:02 GMT 2025 , Edited by admin on Mon Mar 31 22:21:02 GMT 2025
|
PRIMARY | |||
|
970EKW2JTO
Created by
admin on Mon Mar 31 22:21:02 GMT 2025 , Edited by admin on Mon Mar 31 22:21:02 GMT 2025
|
PRIMARY | |||
|
546-18-9
Created by
admin on Mon Mar 31 22:21:02 GMT 2025 , Edited by admin on Mon Mar 31 22:21:02 GMT 2025
|
PRIMARY |